Improving treatment for uterine cancer by targeting DNA damage responses
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
This study is looking for better ways to treat women with advanced or returning uterine cancer by focusing on a problem that makes cancer cells unstable, and it aims to create new therapies using cutting-edge techniques.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11070302 on NIH RePORTER |
What this research studies
This research focuses on addressing the increasing rates of uterine cancer, particularly endometrial cancer, which affects women in the United States. The project aims to improve treatment outcomes for women with advanced or relapsed uterine cancer by targeting replication stress, a condition that leads to genomic instability in cancer cells. The research team, composed of experts from the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, will explore three different strategies to effectively manage this stress and develop new therapies. By utilizing advanced techniques in DNA repair and immunotherapy, the goal is to translate these findings into practical treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with advanced or relapsed endometrial cancer.
Not a fit: Patients with early-stage uterine cancer or those not diagnosed with endometrial cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for women suffering from advanced uterine cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting replication stress in other cancer types, suggesting potential for success in this novel approach for uterine cancer.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Matulonis, Ursula Anne — Dana-Farber Cancer Inst
- Study coordinator: Matulonis, Ursula Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.